Adnan Jamil of Deloitte sets out specific recommendations and emerging leading practices as Life Sciences organisations assess what’s needed from next-generation regulatory information management (RIM)…
Direct pharma-patient engagement used to be considered largely a “nice to have,” and was, at best, a rare occurrence at specific times during the pharmaceutical…
Pharmaceutical companies are placing greater emphasis on consistent and unified data flow throughout their operations, creating a flow of broader data and insights between functions….
Millions of women worldwide are affected by breast cancer, a prevalent form of cancer. For approximately 8 out of 10 cases, invasive ductal carcinoma (IDC)…
The pharmaceutical manufacturing and life sciences industry is in a state of significant disruption, and subsequent transformation. The fallout from COVID, combined with supply chain…
Throughout the 2020s, pharmaceutical companies have been thrust under the spotlight like never before. Fortunately, they’ve largely responded exceptionally, delivering life-saving vaccine treatments at record…
Breakthroughs with immunotherapy and the mRNA platform are heralding a new dawn for cancer treatment. Drs Daina Vanags, Cori Gorman and Christian K Schneider of…
The pharmaceutical industry is expected to grow at a CAGR of 11.34% and reach $486.62 billion by 2028. With such a vast market size and jostling for…
With disruption to the traditional supply chain, managing quality and safety in today’s complex and ever-changing global Life Sciences market can be a challenge. In…
Over time Life Sciences regulatory processes will become increasingly data focused, driven by cross-functional data connectivity requirements and the growing need for structured data submission…
